Reset
Page 1 of 1 Pages
Posts Per Page
Jordan Smith commented 1 month ago
#19702

 

There is a growing body of evidence supporting the vast applicability and superiority of treatment outcomes of stem cell therapies, compared to conventional treatment options. In fact, the unmet needs within this domain have spurred the establishment of many start-ups in recent years. Further, recent studies suggest that mesenchymal stem cells mesenchymal stem cells can be effectively used to improve patients' resistance to the SARS-CoV-2 virus induced pneumonia leading to speedy recovery.

 

To order this 500+ page report, which features 185+ figures and 220+ tables, please visit this link

 

The USD 8.5 billion (by 2030) financial opportunity within the stem cell therapies market has been analyzed across the following segments:

  • Source of stem cell
  • Allogeneic
  • Autologous

 

  • Origin of stem cell
  • Adult
  • Embryonic

 

  • Type of stem cell
  • Hematopoietic
  • Mesenchymal
  • Progenitor
  • Others

 

  • Lineage of stem cell
  • Adipose Tissue
  • Bone Marrow
  • Cord Blood
  • Others

 

  • Route of Administration
  • Intraarticular
  • Intracoronary
  • Intramuscular
  • Intramyocardial
  • Intrathecal
  • Intravenous
  • Surgical Implantations
  • Others

 

  • Therapeutic Area
  • Autoimmune / Inflammatory Disorder
  • Cardiovascular Disorders
  • Metabolic Disorder
  • Musculoskeletal Disorders
  • Oncological Disorders
  • Neurological Disorders
  • Ophthalmic Disorders
  • Others

 

  • End Users
  • Ambulatory Surgery Centers
  • Hospitals
  • Specialty Clinics

 

  • Key Geographies
  • North America
  • Europe
  • Asia-Pacific and Rest of the World

 

The Global Stem Cells Market: Focus on Clinical Therapies, 2020–2030 (Based on Source (Allogeneic, Autologous); Origin (Adult, Embryonic); Type (Hematopoietic, Mesenchymal, Progenitor); Lineage (Amniotic Fluid, Adipose Tissue, Bone Marrow, Cardiosphere, Chondrocytes, Corneal Tissue, Cord Blood, Dental Pulp, Neural Tissue Placenta, Peripheral Blood, Stromal Cells); and Potency (Multipotent, Pluripotent)), report features the following companies, which we identified to be key players in this domain:

  • Anterogen
  • Athersys
  • CHABiotech
  • Cytopeutics
  • Hope Biosciences
  • Japan Regenerative Medicine
  • Lineage Cell Therapeutics
  • Orchard Therapeutics
  • Osiris Therapeutics
  • Pluristem Therapeutics
  • Promithera Biosciences
  • Regenexx
  • Stempeutics Research
  • SCM Life Sciences
  • TICEBA

 

Table of Contents

 

1. Preface

2. Executive Summary


3. Introduction
 

4. Market Landscape
 

5. Company Profiles
 

6. Key Therapeutic Areas
 

7. Assessment of Relative Competition and Growth Opportunities 
 

8. Academic Grants Analysis
 

9. Clinical Trail Analysis
 

10. Stem Cell Manufacturing Market Landscape and KPIs for Evaluating Contract

Services Partners
 

11. Stem Cell Therapy Developers and CMOs: Opportunity Assessment
 

12. Key Commercialization Strategies

 

13. Market Forecast
 

14. Conclusion
 

15. Executive Insights

 

16. Appendix 1: Tabulated Data

 

17. Appendix 2: List of Companies and Organizations

 

 

To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/stem-cells-market/296.html/

 

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com

 


Information!  Use the form below to reply to this forum thread or, to reply to an individual post, use the "Quote" button on the relevant post.